文献类型： 外文期刊

作者： Chao, Xuyuan ¹ ; Yang, Shengjie ¹ ; Zhang, Baoying ¹ ; Zang, Xin ¹ ; Zhang, Jingyi ¹ ; Liu, Xizi ² ; Chen, Lu ¹ ; Qi, Lu ¹ ; Xue, Xiaofeng ² ; Hu, Han ² ; Wang, Xinghe ¹ ;

作者机构： 1.Capital Med Univ, Beijing Shijitan Hosp, PhaseClin Trial Ctr 1, Beijing 100038, Peoples R China

2.Chinese Acad Agr Sci, Inst Apicultural Res, 1 Beigou Xiangshan, Beijing 100093, Peoples R China

3.Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, PhaseClin Trial Ctr 1, Jinan 250117, Peoples R China

关键词： Photocleavable amino graphene; N-Glycans; Human serum; Hepatocellular carcinoma; Cancer biomarker; MALDI-TOF/TOF MS

期刊名称：CANCER NANOTECHNOLOGY （ 影响因子：4.8； 五年影响因子：5.1 ）

ISSN： 1868-6958

年卷期： 2025 年 16 卷 1 期

页码：

收录情况： SCI

摘要： Glycosylation alterations have emerged as significant indicators in the landscape of cancer diagnosis, with aberrant N-glycans standing out as potential biomarkers. The existing methods for purifying N-glycans mainly rely on their hydrophilicity, affinity, and size. These methods exhibit relatively weak binding forces and low specificity based on non-covalent interactions. Moreover, the current liquid chromatography-based N-glycan purification and detection techniques must be bettered for clinical settings' rapid diagnostic requirements. Here, we have developed a method involving the covalent binding of graphene modified with photocleavable amino groups to N-glycans in hepatocellular carcinoma (HCC) patients' serum glycoproteins. The N-glycans are identified using MALDI-TOF/TOF MS, catering to the requirements of biological research and the diagnosis of liver cancer disease. Specifically, amino-functionalized graphene is linked with photocleavable groups bearing hydrazide functional group, then undergoes acyl hydrazone covalent reaction with aldehyde groups on the side chains of oxidized monosaccharides to capture the N-glycans. Finally, under UV irradiation at a wavelength of 356 nm for 15 s, the ortho-nitrobenzyl photocleavable groups undergo cleavage, completing the release of captured N-glycans, which are then subjected to MALDI-TOF/TOF MS mass spectrometry for detection. Our findings demonstrate significant differences in the N-glycan profiles between serum samples of liver cancer patients and healthy individuals. These differences are characterized by increased abundance and molecular weight of N-glycans. Through biomarker screening, one N-glycan with an m/z ratio of 1847.01 shows the potential to serve as a diagnostic biomarker for liver cancer (P < 0.05). Our research underscores the potential of photocleavable amino-modified graphene for detecting aberrant N-glycans in HCC patients' serum to elucidate the intricate between aberrant N-glycan alterations and HCC. This research paves the way for developing novel biomarkers, diagnostic strategies, and therapeutic interventions to combat this complex disease.